NATCO PHARMA
|
NATCO PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 77.56 | 39.19 | 9.32 | 24.16 | 25.32 |
| CEPS(Rs) | 87.99 | 48.17 | 17.13 | 30.65 | 30.65 |
| DPS(Rs) | 9.50 | 5.50 | 4.50 | 5.25 | 6.75 |
| Book NAV/Share(Rs) | 326.99 | 267.06 | 233.44 | 224.88 | 206.04 |
| Tax Rate(%) | 17.04 | 17.01 | 15.92 | 23.67 | 19.45 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 40.43 | 31.64 | 11.89 | 28.97 | 28.31 |
| EBIT Margin(%) | 39.08 | 30.42 | 9.92 | 28.45 | 28.68 |
| Pre Tax Margin(%) | 38.63 | 29.91 | 9.12 | 27.81 | 27.63 |
| PAT Margin (%) | 32.05 | 24.83 | 7.67 | 21.23 | 22.26 |
| Cash Profit Margin (%) | 36.36 | 30.51 | 14.10 | 26.84 | 27.11 |
| Performance Ratios | |||||
| ROA(%) | 22.13 | 13.29 | 3.43 | 9.43 | 10.30 |
| ROE(%) | 25.88 | 15.66 | 4.06 | 11.27 | 12.71 |
| ROCE(%) | 30.08 | 18.06 | 4.86 | 13.99 | 14.82 |
| Asset Turnover(x) | 0.69 | 0.54 | 0.45 | 0.44 | 0.46 |
| Sales/Fixed Asset(x) | 1.24 | 0.89 | 0.76 | 0.86 | 1.07 |
| Working Capital/Sales(x) | 1.42 | 1.24 | 1.25 | 1.15 | 1.25 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.81 | 1.13 | 1.32 | 1.16 | 0.93 |
| Receivable days | 86.16 | 93.53 | 85.10 | 84.44 | 93.77 |
| Inventory Days | 60.81 | 95.32 | 128.47 | 118.77 | 96.38 |
| Payable days | 136.43 | 133.18 | 106.38 | 151.52 | 243.26 |
| Valuation Parameters | |||||
| PER(x) | 12.27 | 14.38 | 81.30 | 34.16 | 19.99 |
| PCE(x) | 10.81 | 11.70 | 44.21 | 26.92 | 16.51 |
| Price/Book(x) | 2.91 | 2.11 | 3.24 | 3.67 | 2.46 |
| Yield(%) | 1.00 | 0.98 | 0.59 | 0.64 | 1.33 |
| EV/Net Sales(x) | 4.11 | 3.66 | 7.21 | 7.33 | 4.94 |
| EV/Core EBITDA(x) | 8.75 | 9.52 | 38.67 | 21.19 | 13.71 |
| EV/EBIT(x) | 9.71 | 11.30 | 63.75 | 25.37 | 16.03 |
| EV/CE(x) | 2.65 | 1.97 | 3.00 | 3.43 | 2.31 |
| M Cap / Sales | 4.26 | 3.80 | 7.11 | 7.34 | 4.81 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 47.72 | 39.20 | -5.23 | 7.16 | -8.57 |
| Core EBITDA Growth(%) | 80.69 | 186.95 | -48.93 | 2.87 | -25.41 |
| EBIT Growth(%) | 93.14 | 298.54 | -62.91 | 0.46 | -30.07 |
| PAT Growth(%) | 94.09 | 320.76 | -61.57 | -3.43 | -28.69 |
| EPS Growth(%) | 97.88 | 320.76 | -61.44 | -4.58 | -28.30 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.06 | 0.03 | 0.09 | 0.06 | 0.08 |
| Current Ratio(x) | 4.14 | 4.39 | 3.50 | 4.46 | 3.39 |
| Quick Ratio(x) | 3.47 | 3.35 | 2.49 | 3.04 | 2.63 |
| Interest Cover(x) | 88.16 | 60.44 | 12.42 | 44.58 | 27.45 |
| Total Debt/Mcap(x) | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 |
Compare Financial Ratios of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹22,197.7 Cr | 2.2% | -14.3% | 47.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹428,557.0 Cr | 2.3% | -0.8% | 32.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,994.0 Cr | 3.2% | 1.1% | 51.5% | Stock Analytics | |
| CIPLA | ₹116,494.0 Cr | 0.3% | -2% | 10% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹109,297.0 Cr | -1.8% | 2.7% | 12.7% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹100,035.0 Cr | 2% | 1.5% | 38% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 2.2% |
-14.3% |
47.1% |
| SENSEX | -1% |
-5% |
5.6% |
You may also like the below Video Courses
